Milvexian
Johnson & Johnson (Janssen) · Bristol Myers Squibb · JNJ-70033093 · BMS-986177
FollowEvery change as it happens, and a Monday email
Trials
3 active
17 in total · 4 in the EU
What this is
- How it works
- Factor XIa inhibitor
- Main trialPhase 3
- “The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.”In the company’s words, NCT05702034 on ClinicalTrials.gov
- Other names
- JNJ-70033093 · BMS-986177
Other drugs for Ischemic Stroke; Ischemic Attack, Transient
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up1
- 8 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Oct 2026 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | |
| Phase 3Active, not recruiting | 8 Dec 2026 | A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | |
| Phase 3Completed | 6 Feb 2026 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome | |
| Phase 2Completed | 6 Apr 2021 | A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery | |
| Phase 2Completed | 31 Mar 2022 | A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel | |
| Phase 1Completed | 4 Mar 2018 | Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment | |
| Phase 1Completed | 19 Feb 2019 | A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects | |
| Phase 1Completed | 8 Apr 2020 | A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants | |
| Phase 1Completed | 14 Nov 2020 | A Study of JNJ-70033093 in Healthy Participants | |
| Phase 1Completed | 9 Jun 2021 | A Study of JNJ-70033093 and Digoxin in Healthy Participants | |
| Phase 1Completed | 22 Aug 2021 | A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants | |
| Phase 1Completed | 25 Oct 2021 | A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants | |
| Phase 1Completed | 4 Dec 2021 | A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants | |
| Phase 1Completed | 6 May 2022 | A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants | |
| Phase 1Completed | 7 Jun 2023 | A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants | |
| Phase 1Completed | 20 Jul 2023 | A Study of Milvexian in Healthy Adult Females | |
| Phase 1Authorised | not given | Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Risk of Thromboembolic Events |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026